Loading...

CASI Pharmaceuticals

DB:ENMN
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ENMN
DB
$320M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
ENMN Share Price and Events
7 Day Returns
4.6%
DB:ENMN
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-46.9%
DB:ENMN
-9.2%
DE Biotechs
-6.7%
DE Market
ENMN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CASI Pharmaceuticals (ENMN) 4.6% 1.3% -12.1% -46.9% 159.6% 110.9%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • ENMN underperformed the Biotechs industry which returned -9.2% over the past year.
  • ENMN underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
ENMN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is CASI Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CASI Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €2.908.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CASI Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CASI Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ENMN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.32
NasdaqCM:CASI Share Price ** NasdaqCM (2019-04-18) in USD $3.34
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CASI Pharmaceuticals.

DB:ENMN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CASI Share Price ÷ EPS (both in USD)

= 3.34 ÷ -0.32

-10.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CASI Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CASI Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CASI Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:ENMN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
63.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CASI Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CASI Pharmaceuticals's assets?
Raw Data
DB:ENMN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.15
NasdaqCM:CASI Share Price * NasdaqCM (2019-04-18) in USD $3.34
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:ENMN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CASI Share Price ÷ Book Value per Share (both in USD)

= 3.34 ÷ 1.15

2.91x

* Primary Listing of CASI Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CASI Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CASI Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CASI Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CASI Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CASI Pharmaceuticals expected to grow at an attractive rate?
  • CASI Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • CASI Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare CASI Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ENMN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ENMN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 63.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ENMN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ENMN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 152 47 1
2022-12-31 116 29 1
2021-12-31 78 8 1
2020-12-31 28 -19 2
2019-12-31 6 -31 2
DB:ENMN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -29 -27
2018-09-30 -14 -23
2018-06-30 -12 -16
2018-03-31 -10 -13
2017-12-31 -6 -11
2017-09-30 -7 -8
2017-06-30 -7 -8
2017-03-31 -6 -9
2016-12-31 -6 -9
2016-09-30 0 -6 -8
2016-06-30 0 -6 -8
2016-03-31 0 -6 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CASI Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if CASI Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ENMN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from CASI Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ENMN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.40 0.40 0.40 1.00
2022-12-31 0.25 0.25 0.25 1.00
2021-12-31 0.07 0.07 0.07 1.00
2020-12-31 -0.19 -0.09 -0.30 2.00
2019-12-31 -0.32 -0.25 -0.39 2.00
DB:ENMN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.32
2018-09-30 -0.30
2018-06-30 -0.23
2018-03-31 -0.20
2017-12-31 -0.18
2017-09-30 -0.12
2017-06-30 -0.13
2017-03-31 -0.15
2016-12-31 -0.17
2016-09-30 -0.21
2016-06-30 -0.23
2016-03-31 -0.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CASI Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CASI Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CASI Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CASI Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CASI Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CASI Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CASI Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CASI Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CASI Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CASI Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ENMN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -27.47 18.79 7.71
2018-09-30 -23.25 14.16 8.37
2018-06-30 -16.11 7.81 7.60
2018-03-31 -12.66 4.35 7.70
2017-12-31 -10.77 3.64 7.11
2017-09-30 -8.40 3.80 4.57
2017-06-30 -8.48 3.80 4.67
2017-03-31 -9.36 4.99 4.35
2016-12-31 -9.45 5.10 4.32
2016-09-30 0.00 -8.48 4.38 4.07
2016-06-30 0.00 -8.39 4.42 3.97
2016-03-31 0.02 -7.20 3.39 3.80
2015-12-31 0.05 -7.21 3.52 3.67
2015-09-30 0.07 -7.10 3.63 3.47
2015-06-30 0.07 -27.03 4.05 3.28
2015-03-31 0.05 -26.55 4.03 2.83
2014-12-31 0.02 -26.20 3.97 2.55
2014-09-30 -25.91 3.83 2.39
2014-06-30 -5.82 3.36 2.46
2014-03-31 -6.05 3.48 2.58
2013-12-31 -5.74 3.17 2.57
2013-09-30 0.67 -4.79 2.99 2.48
2013-06-30 0.67 -4.54 2.84 2.37
2013-03-31 0.67 -13.23 2.40 2.10
2012-12-31 0.67 -14.88 2.87 2.02
2012-09-30 1.93 -13.77 2.83 1.95
2012-06-30 1.93 -14.14 2.80 2.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CASI Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CASI Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CASI Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CASI Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CASI Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CASI Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CASI Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CASI Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CASI Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CASI Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 61.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CASI Pharmaceuticals Company Filings, last reported 3 months ago.

DB:ENMN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 109.46 1.50 85.12
2018-09-30 113.32 1.50 100.03
2018-06-30 83.52 1.50 67.44
2018-03-31 67.62 1.50 51.21
2017-12-31 38.54 1.50 43.49
2017-09-30 15.58 1.50 21.64
2017-06-30 17.03 1.50 23.36
2017-03-31 19.24 1.49 25.53
2016-12-31 20.78 1.49 27.09
2016-09-30 16.02 1.49 24.14
2016-06-30 10.02 1.48 18.53
2016-03-31 4.64 1.47 13.94
2015-12-31 -6.09 1.46 5.13
2015-09-30 -4.73 1.46 6.42
2015-06-30 -3.45 1.44 7.95
2015-03-31 -1.83 1.41 9.46
2014-12-31 -0.42 1.39 10.67
2014-09-30 0.84 1.37 11.82
2014-06-30 12.74 0.00 13.08
2014-03-31 13.86 0.00 14.20
2013-12-31 14.94 0.00 15.13
2013-09-30 15.76 0.00 15.87
2013-06-30 16.79 0.00 17.22
2013-03-31 17.69 0.00 18.27
2012-12-31 8.24 0.00 8.05
2012-09-30 8.36 0.00 8.81
2012-06-30 9.29 0.00 10.06
  • CASI Pharmaceuticals's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CASI Pharmaceuticals has sufficient cash runway for 1.7 years based on current free cash flow.
  • CASI Pharmaceuticals has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 83.2% each year.
X
Financial health checks
We assess CASI Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CASI Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CASI Pharmaceuticals dividends.
If you bought €2,000 of CASI Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CASI Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CASI Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ENMN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ENMN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CASI Pharmaceuticals has not reported any payouts.
  • Unable to verify if CASI Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CASI Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CASI Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CASI Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CASI Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CASI Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CASI Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wei-Wu He
COMPENSATION $781,000
AGE 53
TENURE AS CEO 0 years
CEO Bio

Dr. Wei-Wu He, Ph.D. serves as Executive Chairman of CASI Pharmaceuticals, Inc. since February 23, 2018 and serves as its Chief Executive Officer since April 2019. Dr. He previously served as Chairman of CASI Pharmaceuticals, Inc. from May 2013 to February 23, 2018. Dr. He founded OriGene Technologies, Inc., in 1995 and serves as its Chairman & Chief Executive Officer. Dr. He is a Co-founder and General Partner of Emerging Technology Partners, LLC. He serves as Investment Partner of IDG Investment Company. Dr. He is one of the founding investors in Intradigm. He served as Chairman and Chief Executive Officer of Cytomyx Holdings plc since November 28, 2006. He worked at Human Genome Sciences, Inc. He served as President of OriGene Technologies, Inc. He serves as the Chairman of Genetron Health (Beijing) Co., Ltd. He served as the Chairman of Aptus Pharmaceuticals, Inc. He served as an Executive Chairman of CASI Pharmaceuticals, Inc. from February 2012 to May 2013. He has been Director of CASI Pharmaceuticals, Inc. since February 2012 and Human Longevity, Inc. since July 25, 2016. He serves as Director at MithraGen, Inc., Emerging Technology Partners, Origene Technologies, Inc., Intradigm, Inc., and Amnis, Inc. He served as Director at Adenosine Therapeutics, LLC, Clairus Technologies, Inc., Intradigm Corporation, Amnis Corporation, Aptus Pharmaceutical, Inc., and FasGen, Inc. He served as Director at InforMax, Inc., since August 2000. He has been awarded over 20 U.S. patents and has more than twenty original research publications. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and conducted cancer research at Mayo Clinic and at Massachusetts General Hospital. Dr. He received an M.B.A. degree from the Wharton School.

CEO Compensation
  • Wei-Wu's compensation has been consistent with company performance over the past year.
  • Wei-Wu's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CASI Pharmaceuticals management team in years:

2
Average Tenure
52.5
Average Age
  • The tenure for the CASI Pharmaceuticals management team is about average.
Management Team

Wei-Wu He

TITLE
Executive Chairman & CEO
COMPENSATION
$781K
AGE
53

Cynthia Hu

TITLE
COO, General Counsel & Secretary
COMPENSATION
$467K
AGE
48
TENURE
10.3 yrs

Alex Zukiwski

TITLE
Chief Medical Officer
COMPENSATION
$612K
AGE
61
TENURE
2 yrs

George Chi

TITLE
Chief Financial Officer
TENURE
0.6 yrs

Sara Capitelli

TITLE
VP of Finance & Principal Accounting Officer
COMPENSATION
$222K
AGE
52
TENURE
8.3 yrs

Jim Goldschmidt

TITLE
Senior Vice President

Larry Zhang

TITLE
President of CASI (Beijing) Pharmaceuticals Co.
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the CASI Pharmaceuticals board of directors in years:

4.7
Average Tenure
59
Average Age
  • The tenure for the CASI Pharmaceuticals board of directors is about average.
Board of Directors

Wei-Wu He

TITLE
Executive Chairman & CEO
COMPENSATION
$781K
AGE
53
TENURE
7.2 yrs

James Huang

TITLE
Independent Director
COMPENSATION
$57K
AGE
52
TENURE
6 yrs

Quan Zhou

TITLE
Independent Director
COMPENSATION
$62K
AGE
60
TENURE
2.8 yrs

S. Eckhardt

TITLE
Member of Scientific Advisory Board
TENURE
12.8 yrs

Ken Ren

TITLE
Director
COMPENSATION
$788K
AGE
59
TENURE
4.3 yrs

Alex Wu

TITLE
Independent Director
COMPENSATION
$41K
AGE
54
TENURE
6 yrs

Franklin Salisbury

TITLE
Independent Director
COMPENSATION
$43K
AGE
62
TENURE
4.8 yrs

Rajesh Shrotriya

TITLE
Independent Director
COMPENSATION
$43K
AGE
74
TENURE
4.6 yrs

Ghassan Abou-Alfa

TITLE
Member of Clinical Advisory Board
TENURE
3.8 yrs

Robert Mayer

TITLE
Member of Clinical Advisory Board
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CASI Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CASI Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin’s lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Details
Name: CASI Pharmaceuticals, Inc.
ENMN
Exchange: DB
Founded: 1991
$284,400,630
95,717,052
Website: http://www.casipharmaceuticals.com
Address: CASI Pharmaceuticals, Inc.
9620 Medical Center Drive,
Suite 300,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CASI Common Stock Nasdaq Capital Market US USD 12. Jun 1996
DB ENMN Common Stock Deutsche Boerse AG DE EUR 12. Jun 1996
Number of employees
Current staff
Staff numbers
125
CASI Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.